Stewart James Peter, Shaughnessy John D
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
J Cell Biochem. 2006 May 1;98(1):1-13. doi: 10.1002/jcb.20774.
Multiple myeloma is the most common form of plasma cell dyscrasia and virtually all cases of myeloma exhibit osteolytic lesions, which result in bone pain, pathological fractures, spinal cord compression, and hypercalcaemia. Malignant plasma cells disrupt the delicate balance between bone formation and bone resorption, which ultimately leads to the debilitating osteolytic lesions. This review focuses principally on mechanisms of osteoblast inhibition by malignant plasma cells with emphasis placed on our experimental findings, which support a model for abnormal Wnt signaling in osteoblast suppression. We describe how excessive amounts of soluble Wnt inhibitors secreted by malignant plasma cells in multiple myeloma could promote osteolytic lesions, tumor growth, suppress hematopoiesis, prevent proper engraftment, and expansion of transplanted stem cells. Finally, we detail current therapies shown to disrupt the interaction between the myeloma cell and the microenvironment, leading to activation of osteoblasts.
多发性骨髓瘤是浆细胞发育异常最常见的形式,几乎所有骨髓瘤病例都表现出溶骨性病变,这会导致骨痛、病理性骨折、脊髓压迫和高钙血症。恶性浆细胞破坏了骨形成与骨吸收之间的微妙平衡,最终导致使人虚弱的溶骨性病变。本综述主要关注恶性浆细胞抑制成骨细胞的机制,重点是我们的实验结果,这些结果支持了一种在成骨细胞抑制中Wnt信号异常的模型。我们描述了多发性骨髓瘤中恶性浆细胞分泌的过量可溶性Wnt抑制剂如何促进溶骨性病变、肿瘤生长、抑制造血、阻止移植干细胞的正常植入和扩增。最后,我们详细介绍了目前已证实能破坏骨髓瘤细胞与微环境之间相互作用从而导致成骨细胞活化的疗法。